Companies › Imunon
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IMNN-001 (GEN-1) IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer | IL12 | Phase 3 | Epithelial Ovarian Cancer; Ovarian Cancer | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03393884 | IMNN-001 (GEN-1) | Phase 1 | Epithelial Ovarian Cancer | Oncology | Jul 2024 |
| NCT05739981 | IMNN-001 (GEN-1) | Phase 1 | Ovarian Cancer | Oncology | Jun 2027 |
| NCT06915025 | IMNN-001 (GEN-1) | Phase 3 | Epithelial Ovarian Cancer | Oncology | Oct 2032 |
Cash and short-term investments of $7m on 2026-06-30; operating cash outflow about $14m a year; runway about 6 months at that burn, to Dec 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Strand Therapeutics Geneos Therapeutics Suzhou Abogen Biosciences VLP Therapeutics Sonnet BioTherapeutics Kangabio AUSTRALIA enGene Inovio Pharmaceuticals Trogenix
Genelux BriaCell Therapeutics Actinium Pharmaceuticals Oncolytics Biotech Cardiff Oncology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.